ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to figure out its next move. Now trading with a market value of 6.74M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.
ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For IMUC, the company currently has 5.54 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 6.78 million in total assets, balanced by 7.3 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
ImmunoCellular Therapeutics, Ltd. (IMUC) saw -2.22 million in free cash flow last quarter, representing a quarterly net change in cash of 4.19 million. Perhaps most importantly where cash movements are concerned, the company saw about -2.22 million in net operating cash flow.
ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the IMUC saw sales decline by 0.00.
But what about the bottom line? After all, that’s what really matters in the end. ImmunoCellular Therapeutics, Ltd. (IMUC) is intriguing when broken down to its core data. The cost of selling goods last quarter was 13,941, yielding a gross basic income of -13,941 . For shareholders, given the total diluted outstanding shares of 15.31 million, this means overall earnings per share of -0.40.
Is ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) Valuation Attractive
One should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on ImmunoCellular Therapeutics, Ltd..